

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. BOX 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/790,622		03/01/2004	Ragina Naidu	740082.408C1	8831
500	7590 12/29/2004		EXAMINER		
· <del>··</del> ····		UAL PROPERTY	TRINH, BA K		
701 FIFTH AVE SUITE 6300 SEATTLE, WA 98104-7092				ART UNIT	PAPER NUMBER
				1625	

DATE MAILED: 12/29/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Office A. Communication	10/790,622	NAIDU, RAGINA				
	Office Action Summary	Examiner	Art Unit				
		Ba K. Trinh	1625				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>03</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠	Responsive to communication(s) filed on 7/21/	<u> 2004</u> .					
2a)	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.						
3)	Since this application is in condition for allowar						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims		•				
4)⊠	Claim(s) 1-13 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	5) Claim(s) is/are allowed.						
6)⊠	⊠ Claim(s) <u>1-13</u> is/are rejected.						
	Claim(s) is/are objected to.						
8)[	Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10)⊠ The drawing(s) filed on <u>01 March 2004</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	nder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>							
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
· · · · · · · · · · · · · · · · · · ·							
Attachment	• •	_					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Paper No(s)/Mail Date							
3) 🔲 Inform	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date		atent Application (PTO-152)				
Potent and Tradework Office							

Application/Control Number: 10/790,622

Art Unit: 1625

## **DETAILED ACTION**

Claims 1-13 are pending.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The processes of claims 1-13 do not provide reaction reagent(s) and/or conditions to carry out the claimed invention in each of the steps. The relationships between the starting material and the final product via the intermediate(s) are not adequately shown in the step(s) of the claimed processes.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kingston et al (US 5,470,866).

Kingston et al teaches a process of converting cephalomannine to a taxane intermediate; note compound 12 in Figure 5 and lines 40 to 65 column 5 of the patent. The prior art compound 12 is an analog of the current taxane intermediate which is hydroxy-protected at the C-7 position and the C-2' position. The amine moiety of the prior art taxane intermediate is then further acylated to form taxol( paclitaxel) as shown in Figure 5 or to form taxotere 27 in column 23 of

Art Unit: 1625

the patent; note lines 20 to 65 of column 23 and that taxotere is also named docetaxel. Thus, the claimed process in claims 1-3 would be deemed obvious over the prior art teachings in view of the analogy of the hydroxy-protecting groups in the same amine taxane derivatives.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ba K. Trinh whose telephone number is (571) 272-0695. The examiner can normally be reached on M-F (8:30-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ba K. Trinh Primary Examiner

Art Unit 1625

TRINH/BKT 27 December 2004